These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 17103257)

  • 1. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.
    Dessureault S; Alsarraj M; McCarthy S; Hunter T; Noyes D; Lee D; Harkins J; Seigne J; Jennings R; Antonia SJ
    J Surg Res; 2005 May; 125(2):173-81. PubMed ID: 15854671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
    J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
    ; Celis E
    Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
    Powell A; Creaney J; Broomfield S; Van Bruggen I; Robinson B
    Lung Cancer; 2006 May; 52(2):189-97. PubMed ID: 16563560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
    Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
    Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
    Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.
    Olivares J; Kumar P; Yu Y; Maples PB; Senzer N; Bedell C; Barve M; Tong A; Pappen BO; Kuhn J; Magee M; Wallraven G; Nemunaitis J
    Clin Cancer Res; 2011 Jan; 17(1):183-92. PubMed ID: 21208907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
    Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; W├Âlfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.